Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain.

Maria G Crespo-LeiroRaquel López-VilellaAmador López GranadosSònia MirabetCarles Díez-LópezEduardo Barge-CaballeroJavier Segovia-CuberoFrancisco González-VilchezDiego Rangel-SousaTeresa Blasco-PeiróLuis de la Fuente-GalánBeatriz Díaz-MolinaEduardo Zatarain-NicolásFrancisco Carrasco ÁvalosLuis Almenar-Bonet

Published in: Clinical transplantation (2019)

These results may support the use of dabigatran as an alternative to vitamin K antagonists in patients listed for HT requiring anticoagulation due to NVAF. More studies are needed to reaffirm these observations.

Keyphrases

atrial fibrillation
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
left ventricular
prognostic factors
heart failure
coronary artery bypass
patient reported outcomes
patient reported